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RUNNING HEAD 24 
Clinical covariates impacting detection of glaucoma progression using mGCIPL and pRNFL analysis. 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
ABSTRACT 26 
Purpose: To investigate which clinical measures influence whether an individual demonstrates 27 
earliest glaucomatous structural progression on peripapillary retinal nerve fibre layer (pRNFL) or 28 
macular ganglion cell-inner plexiform layer (mGCIPL).  29 
30 
Design: Prospective longitudinal cohort study. 31 
32 
Participants: 271 eyes from 207 individuals with statistically significant evidence of glaucomatous 33 
progression on optical coherence tomography (OCT)-Guided Progression Analysis
 
(GPA) software 34 
were drawn from a total of 1271 eyes from 686 individuals categorized as glaucoma suspect or 35 
having early manifest glaucoma undergoing glaucoma surveillance. 36 
37 
Methods: Individuals demonstrating earliest evidence of longitudinal progression on mGCIPL GPA 38 
event analysis were compared to individuals demonstrating evidence of earliest longitudinal 39 
progression on pRNFL GPA event analysis.  40 
41 
Outcome Measures: Correlation of OCT event change analysis with intraocular pressure (IOP), 42 
clinical variables, and baseline thickness of the pRNFL and mGCIPL.  43 
Results: IOP, baseline pRNFL thickness, baseline mGCIPL thickness and systemic hypertension were 44 
associated with location of first progression. Eyes demonstrating earliest longitudinal progression on 45 
mGCIPL had significantly lower maximum-recorded pre-treatment IOP (mean difference: 3.90mmHg, 46 
95%CI: 2.37-5.43; p<0.001). The time interval between progression on pRNFL and progression on 47 
mGCIPL increased by 12.4 months for every 5mmHg increase in IOP (95%CI: 10.32 -15.72). Eyes 48 
demonstrating earliest longitudinal progression on mGCIPL had significantly lower baseline average 49 
pRNFL thickness than eyes progressing on pRNFL first (mean difference: 7.07μm; 95%CI: 4-38-9.77; 50 
p<0.001). Eyes progressing first on mGCIPL parameters were 3.03 times more likely to develop a 51 
new paracentral field defect than cases progressing first on pRNFL parameters (OR: 3.03; 95%CI: 52 
1.26-7.28; p=0.01).  53 
54 
Conclusion: Clinical features, particularly pre-treatment IOP, influence whether structural glaucoma 55 
progression is detected earlier with mGCIPL or pRNFL imaging. These data support the utility of 56 
mGCIPL imaging in addition to pRNFL analysis for detection of glaucoma progression, particularly in 57 
patients with normal IOP.  58 
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ABBREVIATIONS: 59 
60 
mGCIPL: macular ganglion cell-inner plexiform layer 61 
pRNFL: peripapillary retinal nerve fibre layer 62 
IOP: intraocular pressure 63 
NTG: normal tension glaucoma 64 
HTG: high tension glaucoma 65 
GPA: guided progression analysis 66 
RGC: retinal ganglion cell 67 
OCT: optical coherence tomography 68 
SITA: Swedish Interactive Threshold Algorithm 69 
HVF: Humphrey Visual Field 70 
EMG: Early Manifest Glaucoma 71 
GS: Glaucoma Suspect 72 
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INTRODUCTION 73 
Spectral domain optical coherence tomography (SD-OCT) provides quantitative information about 74 
glaucomatous degeneration of retinal ganglion cell (RGC) components at the macula and 75 
peripapillary retinal nerve fibre layer (pRNFL). Assessment of pRNFL thickness has become routine in 76 
clinical glaucoma practice. Over the past decade, evidence has accrued to indicate that OCT changes 77 
at the macular ganglion cell-inner plexiform layer (mGCIPL) are also highly informative. Hou et al 78 
showed that in patients with confirmed glaucoma, mGCIPL monitoring is a more specific OCT metric 79 
for detecting further progression than pRNFL monitoring (95.5% vs 91.0% ).
1
 The mGCIPL has a 80 
theoretical advantage over the pRNFL for detecting RGC degeneration, because 50% of RGCs are 81 
located at the macula, and RGC cell bodies are 10-20x thicker than their axons adjacent to the optic 82 
nerve head.
2
  83 
84 
Several longitudinal studies have compared the ability of mGCIPL and pRNFL imaging to detect 85 
glaucoma progression, but the influence of clinical parameters, such as intraocular pressure (IOP), 86 
on the relative utility of these two testing strategies has received limited attention. The only clinical 87 
parameter to have been studied in detail is glaucoma severity. In moderate and advanced glaucoma, 88 
mGCIPL imaging is superior at detecting progression than pRNFL imaging,
3,4
 whereas in earlier stages 89 
of the disease the two testing strategies are approximately equivalent.
1,3–6
 It is unknown whether 90 
other ocular or systemic characteristics influence the timing and location of structural progression. 91 
The purpose of this study was to investigate covariates that could help to predict whether glaucoma 92 
progression on SD-OCT is likely to be detected earlier at the optic disc or macula.   93 
94 
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METHODS  95 
Participants 96 
This investigation was a subanalysis of an ongoing, longitudinal, prospective, multi-centre 97 
observational cohort study of individuals initially classified as glaucoma suspect (GS) or having early 98 
manifest glaucoma (EMG) in South Australia. Inclusion criteria were: age between 18 and 85 years, 99 
and the ability to provide written consent, to perform reliable automated perimetry and to attend 6-100 
monthly visits. Participants classified as GS and EMG were consecutively recruited at the Flinders 101 
Medical Centre and private ophthalmology practices in South Australia. EMG was defined as 102 
glaucomatous optic disc changes (disc grade ≥ 3 on the Disc Damage Likelihood Scale (DDLS)
7
 in the 103 
presence of early glaucomatous field changes (mean deviation better than -6dB), as per Hoddapp-104 
Parrish-Anderson (HPA) criteria on at least 2 reliable Humphrey Visual Field (HVF) 24-2 SITA Standard 105 
Tests (Humphrey Field Analyzer; Carl Zeiss Meditec; Dublin, CA).
88
  The criteria for a reliable HVF 106 
included: fixation loss of 33% or less, false positive rates of 33% or less, and false-negative rates of 107 
33% or less. Glaucoma suspects were defined as participants with an optic nerve head or neuro-108 
retinal rim appearance suspicious of glaucoma but without a glaucomatous visual field defect as per 109 
HPA criteria on a reliable HVF 24-2 SITA Standard test. A suspicious optic nerve head or neuroretinal 110 
rim was defined by a DDLS grade of 1 or 2 on stereo disc photography.
7
 111 
 112 
Enrolled participants underwent six-monthly ophthalmic evaluation. IOP measurements were 113 
undertaken using Goldmann applanation tonometry. Longitudinal IOP data was reviewed to 114 
determine maximum, minimum, mean and maximum pre-treatment IOP. In cases where patients 115 
were already on treatment at baseline, patient records were reviewed to determine maximum IOP 116 
prior to treatment commencement. Optic disc and structural assessment were undertaken using slit 117 
lamp examination and stereo-photography of the optic disc, and SD-OCT analysis of the pRNFL and 118 
mGCIPL. Longitudinal visual field data was obtained using achromatic HVF 24-2 SITA Standard 119 
perimetry. Reliable HVFs were assessed for visual field progression using the HPA criteria.  Spatial 120 
assessment of visual field defects was undertaken as per Kang et al
9
 whereby the paracentral visual 121 
field was deemed to be the central 16 points in the 24-2 pattern. The peripheral visual field was 122 
deemed to be all other areas of the visual field (i.e. nasal steps, bjerrum or temporal wedge). New 123 
visual field defects were subsequently characterised as either: paracentral only, peripheral only, or 124 
both paracentral and peripheral. The study protocol allowed participants to have additional reviews 125 
during the six-month interval, with additional HVF and SD-OCT testing performed, if the treating 126 
clinician felt that their clinical situation warranted more frequent follow-up. Participants’ past 127 
medical and medication history was obtained at study enrolment and reviewed during monitoring 128 
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using a general health screening. This health screening consisted of a questionnaire and a baseline 129 
assessment of systolic and diastolic blood pressure. 130 
 131 
Clinical management was at the discretion of the treating ophthalmologist. The study design allows 132 
individualized treatment of participants and therefore provides maximal generalizability to the 133 
ophthalmic community, particularly in regions with a predominantly Anglo-European population.  134 
Patient treatment data was also obtained to assess whether different classes or IOP lowering 135 
medications would influence the site of structural progression. This study followed the tenets of the 136 
Declaration of Helsinki, and ethical approval for this study was granted by the Southern Adelaide and 137 
Flinders University Clinical Research Ethics Committee, South Australia.  138 
 139 
Optical Coherence Tomography imaging 140 
SD-OCT imaging was performed using the CIRRUS HD-OCT (Carl Zeiss, Meditec; Dublin, CA). pRNFL 141 
and mGCIPL imaging was performed with optic disc and macular cube scans, respectively. Upon 142 
enrolment, each participant in this study underwent 2 baseline optic disc and macular cube scans, 143 
and repeat optic disc and macular cube scans performed at every subsequent review (6 monthly). 144 
SD-OCT scans were captured by an experienced operator using CIRRUS FastTrac eye-tracking 145 
technology. Scans with a signal strength of <7, motion artefact, poor centration, or segmentation 146 
errors were discarded by the operator and rescanning was performed at the same visit. Scans were 147 
re-checked for artefact by an investigator (HM) before being included in GPA calculations.  148 
 149 
Guided Progression Analysis 150 
GPA data from CIRRUS HD-OCT Software version 9.5 was reviewed. GPA quantitates progressive 151 
thinning of the pRNFL and mGCI L using both event analysis and trend analysis. Event analysis 152 
evaluates change in pRNFL and mGCIPL thickness in individual superpixels (1 superpixel = 4 x 4 153 
pixels) between the follow-up scan and the two baseline scans. Three summary parameter graphs 154 
summarise overall change in the mGCIPL and pRNFL thickness by plotting the mean superior 155 
thickness, mean inferior thickness, and mean total thickness of the mGCIPL and pRNFL. Using event 156 
analysis, a data point is colored yellow (“possible loss”) on the summary parameter graph when the 157 
value falls outside the range of test-retest variability, and is colored red (“likely loss”) if the change is 158 
confirmed on a subsequent follow-up scan. Trend analysis assesses for a statistically significant rate 159 
of thinning over time by performing linear regression of the data points in each of the 3 summary 160 
parameters of mGCIPL and pRNFL (average, superior, and inferior thickness).  161 
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This study was a review of mGCIPL and pRNFL GPA event analysis using the average, superior, and 162 
inferior thickness summary parameters. We classified individuals as having robust evidence of SD-163 
OCT progression if they showed “likely loss” (red data points) on two consecutive visits in any 164 
mGCIPL or pRNFL summary parameter (Figure 1). Individuals therefore required at least 5 SD-OCT 165 
scans (2 baseline scans at their enrolment visit and 3 follow-up scans) to reach this study’s endpoint 166 
for inclusion in the analysis. This highly stringent definition of progression was chosen to offset any 167 
possibility of stable individuals being erroneously classified as demonstrating progression due to 168 
test-retest variability of individual scans (a false positive result). If an individual showed “likely loss” 169 
on two consecutive visits in a mGCIPL summary parameter before any pRNFL summary parameter, 170 
then they were classified as ‘mGCIPL-first’. Conversely, if an individual showed “likely loss” on two 171 
consecutive visits in a pRNFL summary parameter before any mGCIPL summary parameter then they 172 
were classified as ‘pRNFL-first’. Individuals demonstrating earliest longitudinal structural progression 173 
on mGCIPL (classified as ‘mGCIPL-first’) were compared to individuals demonstrating earliest 174 
longitudinal structural progression on pRNFL (classified as ‘pRNFL-first’). Individuals demonstrating 175 
earliest longitudinal progression on pRNFL and mGCIPL at the same time point were excluded from 176 
the comparative analysis.  177 
 178 
Figure 1. A representative individual progressing on mGCIPL-first. 179 
Individuals were classified using the Guided Progression Analysis (GPA) software of the CIRRUS HD-180 
OCT (mGCIPL is displayed in rows a and b, and pRNFL in rows c, d). Rows ‘a’ and ‘c’ are thickness 181 
maps, rows ‘b’ and ‘d’ are thickness change maps (from baseline) and rows ‘e-g’ are graphs of 182 
thickness summary parameters of mGCIPL and pRNFL. This individual had 2 baseline scans 183 
performed upon enrolment at age 74 years. The interval between baseline scans was so small that 184 
the 2 baseline data points appear as 1 on the summary parameter graphs. The mGCIPL GPA event 185 
analysis shows “possible loss” at Exam 5 in both the average (row e) and inferior (row g) thickness 186 
summary parameters, indicated by orange shading of the data point (orange arrows). These 187 
parameters are shaded red (“likely loss”) in Exams 6-8 (red arrows). The mGCIPL thickness change 188 
map indicates the area where structural change is occurring. In contrast, the pRNFL GPA event 189 
analysis has not shown “possible” (orange) or “likely loss” (red), even by Exam 8. This eye was 190 
therefore classified as ‘mGCIPL-first’, with this study’s end-point being reached at Exam 7 (“likely 191 
loss” on 2 consecutive scans). 192 
  193 
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Statistical Analysis: 194 
Baseline data for mGCIPL-first cases were compared to pRNFL-first cases across a range of 195 
demographic and clinical characteristics, including age, sex, eye enrolled, duration of follow-up, IOP, 196 
central corneal thickness, refraction, optic disc area, vertical cup-disc ratio, glaucoma treatment, 197 
baseline pRNFL and mGCIPL thickness, and comorbid medical conditions.  198 
Differences in independent variables between the dichotomous categorical outcome (mGCIPL-first 199 
or pRNFL first) were tested statistically by fitting a univariate generalised linear model (GLM) with 200 
mixed-effects to account for inter-eye correlation. GLMs were fitted with the glmer() function in the 201 
lme4 package (v1.1-18-1) in R (v3.4.1). A multivariate generalised linear model with mixed effects 202 
was then fitted using careful consideration of those variable likely to explain or confound the 203 
outcome, as well as a combination of stepwise variable selection for variables with a p-value <0.1 on 204 
univariate analysis. Random effects on intercept were fitted at the single level of individual patient 205 
ID to account for inter-eye correlation.  206 
Receiver operating characteristic (ROC) curves were constructed and Youden’s index was used to 207 
determine the IOP values and baseline retinal thickness values that optimally distinguished mGCIPL-208 
first cases from pRNFL-first cases. The predictive performance of threshold values was evaluated 209 
using Fisher’s exact test and positive predictive values.  210 
All of the continuous variables studied followed a normal distribution based on the Shapiro-Wilk test 211 
and graphical Q-Q plots. Statistical analyses were performed using freely available R software 212 
(v3.4.1) and commercially available software SPSS for Windows version 23 (SPSS Inc., Chicago, IL, 213 
USA). Reported p values are 2 sided and the probability level for statistical significance was initially 214 
set at 0.05. As this study evaluated 36 independent systemic and ocular variables, this threshold 215 
value was subsequently adjusted to 0.001 after Bonferroni correction.   216 
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RESULTS  217 
Figure 2 shows a flow chart depicting how eyes were selected for this study. CIRRUS HD-OCT GPA 218 
data were reviewed for 1271 eyes of 686 participants. A total of 389 eyes were excluded due to 219 
insufficient SD-OCT scans and 74 eyes were excluded for inadequate scan quality, leaving 808 eyes 220 
from 452 participants with sufficient duration of follow-up and scan quality to reach the study 221 
endpoint. There were 271 eyes of 207 individuals that reached this study’s endpoint of robust SD-222 
OCT progression. 26 eyes (4%) demonstrated structural progression on pRNFL and mGCIPL 223 
parameters at the same time point and were excluded from analysis, leaving 245 eyes from 188 224 
participants.  111 eyes (45.3%) from 80 participants demonstrated structural progression on pRNFL-225 
first, of which 77 demonstrated structural progression on the average summary parameter, 59 226 
demonstrated progression on the superior quadrant summary parameter and 71 cases 227 
demonstrated progression first on the inferior quadrant parameter. 71 of the 77 cases (92%) 228 
progressing on the average pRNFL parameter also demonstrated focal progression on either the 229 
superior or inferior summary parameters. 134 eyes (54.7%) from 108 participants demonstrated 230 
structural progression on mGCIPL-first. 117 mGCIPL-first eyes progressed on the average summary 231 
parameter, 69 mGCIPL-first eyes progressed on the superior summary parameter and 87 mGCIPL-232 
first eyes progressed on the inferior summary parameter. 104 of the 117 cases (88.9%) that 233 
progressed on the average mGCIPL parameter also demonstrated focal progression on either the 234 
superior or inferior summary parameter. In total, 6282 pairs of optic disc and macular cube scans 235 
(12,564 scans) were included for progression analysis.  236 
 237 
Figure 2: Selection and classification of eyes using CIRRUS SD-OCT Software 238 
GS = glaucoma suspect; EMG = early manifest glaucoma  239 
 240 
Analysis of participant demographics and medical history  241 
The mean age for the entire cohort was 66.72 ± 9.15 years, 44.5% were male and the mean duration 242 
of follow-up was 32.43 ± 14.36 months. Univariate analyses into patient demographics and medical 243 
history revealed that although individuals demonstrating earliest longitudinal structural progression 244 
on mGCIPL (mGCIPL-first) had a higher rate of systemic hypertension than individuals progressing on 245 
pRNFL-first, there were no significant differences between mGCIPL-first individuals and pRNFL-first 246 
individuals in terms of age, duration of follow-up, sex, eye reaching endpoint, or other systemic 247 
medical conditions (Table 1). 248 
 249 
 250 
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Analysis of ocular structural characteristics  251 
Eyes progressing on mGCIPL-first had a significantly thinner pRNFL and mGCIPL at baseline than eyes 252 
progressing on pRNFL-first (Table 2). Baseline average pRNFL thickness had the strongest association 253 
with progression on pRNFL-first or mGCIPL-first (p<0.001). Hedges’ g test for comparing baseline 254 
average pRNFL thickness between mGCIPL-first cases and pRNFL-first cases was 0.64, indicating large 255 
effect size. There were no significant differences between mGCIPL-first eyes and pRNFL-first eyes in 256 
terms of central corneal thickness, optic disc area, vertical cup-disc ratio, or refractive error.  257 
 258 
Analysis of ocular clinical characteristics  259 
Eyes progressing on mGCIPL-first had significantly lower maximum recorded pre-treatment IOP 260 
(p<0.001) and maximum recorded IOP (p=0.001), as well as lower mean and minimum IOP values 261 
(p=0.006, p= 0.035 respectively) (Table 3). The IOP measurement that was most strongly associated 262 
with progression on pRNFL-first or mGCIPL-first was maximum recorded pre-treatment IOP. There 263 
was no statistically significant difference in the prevalence of glaucoma treatment prior to structural 264 
progression between the two groups.  There also was no statistically significant difference in the 265 
prevalence of cases treated with Prostaglandin Agonists, Beta-blockers, Alpha-2- agonists or 266 
Carbonic Anhydrase Inhibitors (Table 3).  267 
 268 
Logistic Regression analysis 269 
A multivariate logistic regression was performed to evaluate how systemic and ocular covariates 270 
influenced the probability that a patient would progress on pRNFL-first. We evaluated covariates 271 
with a p-value <0.1 on univariate analysis, and to prevent co-linearity, only the most significant 272 
variable within each subgroup of IOP, baseline pRNFL and baseline mGCIPL variables was selected. 273 
The following variables were assessed: maximum-recorded pre-treatment IOP, baseline average 274 
pRNFL thickness, baseline inferior mGCIPL thickness, and systemic hypertension. Initial analysis 275 
demonstrated that baseline inferior mGCIPL thickness did not statistically significantly contribute to 276 
the model (P=0.419). These were subsequently excluded. The final model was expressed with the 277 
formula: 278 
 279 
mGCIPL/pRNFL ~ max pre-treatment IOP + baseline pRNFL thickness (µM) + hypertension + (1|ID) 280 
where; (1|ID) represents the random effect on slope for each participant. 281 
 282 
In the final model, maximum pre-treatment IOP had the largest effect on OCT progression pattern 283 
(OR 1.19, 95% CI: 1.077-1.316; P<0.001). That is, for every 5 mmHg increase in maximum-recorded 284 
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pre-treatment IOP, the odds of progressing first on pRNFL increased 2.5 times. Baseline pRNFL 285 
thickness had a more modest effect on the OCT progression pattern (OR 1.10, 95% CI: 1.03-1.17; 286 
P=0.002). For every 10µm increase in baseline pRNFL thickness, the odds of progressing first on 287 
pRNFL increased 2.5 times. Finally, a concurrent diagnosis of hypertension showed a trend towards 288 
affecting OCT progression pattern (OR 0.33, 95% CI: 0.11-1.02; P=0.055). 289 
 290 
Sub-analysis of treatment naive individuals 291 
To investigate the possible confounding effects of IOP treatment, a sub-analysis was performed of 292 
individuals who were treatment naive during the period of SD-OCT progression (n=131 eyes (48%), 293 
mGCIPL-first = 78 eyes, pRNFL-first = 53 eyes). Treatment naive eyes progressing on pRNFL-first had 294 
significantly higher maximum-recorded IOP (OR 1.4, 95% CI: 1.03-1.96; P=0.030), with an effect size 295 
greater than was observed in the general cohort. Treatment naive eyes progressing on pRNFL first 296 
also had a greater baseline pRNFL thickness (OR 1.15, 95% CI:1.01-1.32; P=0.031) than those 297 
patients progressing on mGCIPL-first.  298 
 299 
Sub-analysis of Early Manifest Glaucoma and Glaucoma Suspects  300 
The baseline visual field data for all patients was reviewed and 8 eyes were excluded because of 301 
missing baseline visual fields. Sub-analyses were performed for individuals classified as Early 302 
Manifest Glaucoma (EMG) at baseline (n=89 eyes, 37%) and individuals classified as Glaucoma 303 
Suspect (GS) at baseline (n=146 eyes, 63%).  304 
 305 
A multivariate generalised linear model with mixed effects was fitted to baseline EMG/GS 306 
classification for the variables of baseline IOP and RNFL thickness at baseline. Firstly, patients with 307 
thinner baseline average pRNFL were more likely to be EMG cases than GS cases (OR 0.93, 95% 308 
CI:0.89-0.97; P<0.001). EMG and GS case had similar maximum recorded pre-treatment IOP (OR 309 
0.94, 95% CI:0.87-1.00; P=0.062; Supplementary Material, Table 1).  310 
 311 
Considering EMG cases alone, the relationship between pattern of OCT progression and the 312 
explanatory variables of maximum IOP and baseline RNFL thickness was sustained. Eyes progressing 313 
on mGCIPL-first had a significantly lower maximum-recorded pre-treatment IOP than eyes 314 
progressing on pRNFL-first (OR 0.81, 95% CI:0.66-0.98; p=0.032). Eyes progressing on mGCIPL-first 315 
also had lower baseline average pRNFL thickness (OR 0.91, 95% CI:0.84-0.99; p=0.031).  316 
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For GS cases, eyes progressing on mGCIPL-first showed a trend towards a lower maximum-recorded 317 
pre-treatment IOP (OR 0.79, 95% CI:0.60-1.02; P=0.073), and a similar baseline average pRNFL 318 
thickness (OR 0.98, 95% CI:0.83-1.14; P=0.75).  319 
 320 
Correlation of Structural and Functional progression 321 
This study also correlated the structural progression observed on mGCIPL and pRNFL monitoring to 322 
visual field progression on HVF assessments. 82 cases (n = 47 GS cases and n = 35 EMG cases) 323 
demonstrated a new or worsening visual field defect during monitoring, as per the HPA criteria. Of 324 
the 82 cases, 40 cases were mGCIPL-first progressing cases and 42 cases were pRNFL first 325 
progressing cases. 20 eyes demonstrated only paracentral defects, 34 eyes demonstrated only 326 
peripheral defects and 31 eyes demonstrated both paracentral and peripheral defects. Eyes 327 
progressing first on mGCIPL parameters were 3.03 times more likely to develop a new or worsening 328 
paracentral field defect than cases progressing first on pRNFL parameters (OR: 3.03; 95%CI: 1.26-329 
7.28; P=0.01). Eyes progressing first on pRNFL parameters were 1.79 times more likely to develop a 330 
new or worsening peripheral field defect than cases progressing first on mGCIPL (OR: 1.79; 95%CI: 331 
1.12-2.86; P=0.01). Cases that demonstrated solely a new or worsening peripheral visual field defect 332 
had a statistically significantly higher maximum recorded pre-treatment IOP than eyes that 333 
demonstrated a new or worsening paracentral visual field defect (mean difference: 2.96mmHg; 334 
95%CI: 0.48-5.44; P=0.02).  335 
 336 
Subanalysis of individuals progressing on both pRNFL and mGCIPL 337 
In total, 93 eyes reached this study’s endpoint for structural progression on both mGCIPL and pRNFL 338 
but at different time points. A sub-analysis was performed to evaluate how the maximum recorded 339 
pre-treatment IOP impacted the time interval between progression being demonstrated on mGCIPL 340 
and pRNFL. For every 5mmHg increase in maximum-recorded pre-treatment IOP, the interval 341 
between progression on pRNFL and mGCIPL extended by 12.4 months (95%CI: 10.32 -15.72; R-342 
squared=0.857). In eyes with a maximum recorded pre-treatment IOP <14mmHg, progression on 343 
mGCIPL preceded progression on pRNFL by approximately 14.02±8.40 months, whereas in eyes with 344 
a maximum recorded pre-treatment IOP >30mmHg, progression on mGCIPL lagged behind pRNFL 345 
progression by approximately 31.29±2.41 months (Figure 3). 346 
 347 
Figure 3: Impact of maximum recorded pre-treatment IOP on the time interval between 348 
progression being demonstrated on pRNFL and mGCIPL 349 
  350 
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Legend: For each value of maximum recorded pre-treatment IOP, the mean time interval between 351 
progression being demonstrated on mGCIPL and pRNFL was plotted. A positive value indicates that 352 
progression on pRNFL occurred prior to progression on mGCIPL.  353 
 354 
A multiple linear regression analysis was conducted to evaluate how maximum recorded pre-355 
treatment IOP and baseline average pRNFL thickness affected the time interval between progression 356 
on pRNFL and progression on mGCIPL. For every increase of 5mmHg in maximum pre-treatment IOP, 357 
the timing of progression on pRNFL relative to mGCIPL increased by 0.59 years (95%CI: 0.28-0.90, 358 
p<0.001) and for every 5µm increase in baseline average pRNFL, the time interval increases by 0.17 359 
years (95%CI: 0.015-0.32, p=0.03).   360 
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Integration of baseline pRNFL thickness and maximum recorded pre-treatment IOP 361 
Figure 4 shows the ROC curve for maximum recorded pre-treatment IOP and baseline average 362 
pRNFL thickness. Combining these variables resulted in higher predictive performance than either 363 
variable in isolation (AUC for combination ROC curve = 0.771; 95%CI: 0.684-0.8570). When these two 364 
variables operate in tandem, the optimal threshold values are 22.0mmHg for maximum recorded 365 
pre-treatment IOP and 80.5µm for average baseline pRNFL thickness. 366 
 367 
Figure 4: ROC curves for maximum recorded pre-treatment IOP and baseline average pRNFL 368 
thickness 369 
 370 
Figure 5 illustrates the distribution of pRNFL-first and mGCIPL-first progressing cases, according to 371 
whether the maximum recorded pre-treatment IOP and baseline average pRNFL is greater or less 372 
than the optimal threshold values. Individuals with a maximum recorded pre-treatment IOP < 373 
22mmHg and baseline average pRNFL thickness < 80.5um were 2.91 times more likely to progress on 374 
mGCIPL-first than pRNFL-first (positive predictive value 74.6%; 95%CI: 73.3-89.1%). In contrast, 375 
individuals with a maximum-recorded pre-treatment IOP ≥ 22mmHg and baseline thickness ≥ 376 
80.5um were 3.6 times more likely to progress on pRNFL-first than mGCIPL-first (positive predictive 377 
value 69.7%; 95%CI: 53.8-82.0%). 378 
 379 
Figure 5: Distribution of pRNFL-first and mGCIPL-first progression according to IOP and baseline 380 
pRNFL thickness 381 
  382 
Legend: Each quadrant shows the distribution and the proportion of eyes demonstrating 383 
progression on pRNFL-first or mGCIPL-first. Quadrants are defined according to the optimal 384 
threshold values for maximum recorded pre-treatment IOP (22mmHg, horizontal line) and baseline 385 
average pRNFL thickness (80.5μm, vertical line).  386 
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DISCUSSION 387 
Although both optic disc and macula parameters have excellent specificity for glaucoma 388 
progression,
1
 several investigators have used Venn diagrams to elegantly illustrate that in the 389 
majority of progressing individuals, structural progression is detected on only one of the two tests.
1,3
 390 
Hou et al recently demonstrated that although pRNFL progression and mGCIPL progression are 391 
mutually predictive, neither test can substitute for the other and both parameters may be used in 392 
combination to optimise early detection of disease progression in glaucoma patients.
1
 This is the 393 
first study to specifically investigate covariates impacting on the relative utility of optic disc and 394 
macula parameters to detect longitudinal structural change. We found that IOP and baseline pRNFL 395 
thickness are predictive of whether structural progression will be detected first at the optic disc or 396 
macula, which in turns predicts whether a patient is more likely to first manifest a paracentral or 397 
peripheral visual field defect.  398 
 399 
Our results support a novel association between lower IOP and glaucomatous structural change 400 
manifesting at the mGCIPL prior to the pRNFL. Of all ocular and extra-ocular covariates studied, 401 
maximum pre-treatment IOP had the strongest association with the site that first demonstrated 402 
statistically significant structural progression after study enrolment. The pathophysiological 403 
explanation for this observation remains unclear. However, one biologically plausible explanation is 404 
that those individuals with lower IOPs form an endophenotype of glaucoma which manifests loss of 405 
thickness in the mGCIPL earlier than at the peripapillary axons. Whether this difference is related to 406 
macular ganglion cell somata, ganglion cell dendrites, or other retinal cell subtypes remains to be 407 
determined.  The CIRRUS SD-OCT, like most OCT platforms, does not segment the Retinal Ganglion 408 
Cell layer (GCL) from the Inner Plexiform Layer (IPL) as the border between these structures is not 409 
readily distinguishable, therefore we do not yet know whether earliest structural change is being 410 
driven by the GCL, IPL, or both. Conceivably, structural change within the ganglion cell and inner 411 
plexiform layers is more widespread throughout the retina, but is detected at the macula because 412 
that is where the SD-OCT is targeted. Using a cross-sectional design, Kim et al reported that 413 
glaucomatous RNFL defects tended to occur closer to the macula in individuals with lower IOP than 414 
those with higher IOP,
10
 but no other studies have investigated this association.  415 
 416 
It is interesting that the optimal threshold level of maximum pre-treatment IOP as determined by 417 
our analysis was in the range of 21-22mmHg which is comparable to historical cut-offs between 418 
Normal Tension Glaucoma (NTG) and High Tension Glaucoma (HTG) in caucasian populations.
11–14
 419 
We recognise that this is an arbitrary value which relates specifically to the entry criteria and cases 420 
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included in our study. It may be useful to highlight the distribution of pRNFL-first and mGCIPL-first 421 
cases by IOP, but our results are not necessarily generalisable to other populations or patient 422 
subgroups. This study did not set out to categorise participants into HTG and NTG subtypes, 423 
preferring to consider all participants as being part of a continuous spectrum. Nonetheless, our 424 
finding that individuals with lower pre-treatment IOP tended to demonstrate earliest longitudinal 425 
progression on mGCIPL is consistent with what has historically been represented in the literature in 426 
regards to the NTG phenotype. This is further supported by our finding that patients demonstrating 427 
structural progression first on mGCIPL are more likely to develop a paracentral field defect. NTG is 428 
reportedly associated with focal glaucomatous damage at the macula and visual field defects that 429 
are central or paracentral.
12,15,16
 Macular parameters on SD-OCT are therefore well-suited to detect 430 
glaucomatous damage in such patients,  in contrast to pRNFL parameters which have been reported 431 
to be less sensitive at detecting glaucomatous macula defects.
17,18
 In this study, eyes with early 432 
macular progression were therefore associated with several features consistent with historic 433 
descriptions of NTG.
19
  434 
 435 
The current understanding of the cytoskeletal changes during glaucoma might explain the 436 
association between IOP and the site of initial detectable structural defects. The pRNFL is comprised 437 
mostly of retinal ganglion cell axons, whereas the mGCIPL contains the RGC cell bodies, RGC 438 
dendrites and RGC axons.
2
 Several studies have suggested that elevated IOP compresses axons at 439 
the level of the lamina cribrosa to induce retrograde axonal deterioration.
20–22
 It is biologically 440 
plausible that individuals with elevated IOP could manifest structural progression on pRNFL-first, as 441 
we found in this study. In individuals with normal IOP, the same pathological process of retrograde 442 
axonal deterioration at the optic nerve head may be less relevant. It is therefore possible that 443 
glaucoma participants with lower IOP lose retinal ganglion cells via an alternative pathogenic 444 
pathway.
16
 This would be in agreement with our findings and those of Jung et al and Baniasadi et al. 445 
These two studies showed that NTG causes focal thinning of the macula, whereas HTG causes more 446 
diffuse thinning.
23,24
 The integration of these findings with our work suggests that the transition 447 
along the POAG spectrum from NTG to HTG is associated with an endophenotype transition from 448 
focal, deep macula-first structural defects to diffuse, shallow optic-disc first structural defects. 449 
Although more research is required to investigate this hypothesis and to characterise the structural 450 
changes observed, our results illustrate an interesting association between IOP and the initial site of 451 
detectable structural progression.  452 
 453 
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Three previous studies have used trend analysis of OCT data to evaluate rates of mGCIPL and pRNFL 454 
thinning in individuals with progressive mild and advanced POAG.
4,5
 In these studies, the rate of 455 
pRNFL thinning slowed dramatically in advanced glaucoma, whereas the rate of mGCIPL thinning 456 
remained relatively steady in advanced disease and still maintained good sensitivity for detecting 457 
progression.
4,6,25
 This may help explain why patients with thinner pRNFL at baseline were more likely 458 
to progress first on mGCIPL monitoring. In contrast, mGCIPL and pRNFL have been found to have 459 
similar efficacy for detecting progression in mild glaucoma.
4,5
 Our study excluded individuals with 460 
mean deviation worse than -6dB, and yet we still found that even in this cohort of early manifest 461 
glaucoma and glaucoma suspects, baseline pRNFL and mGCIPL thickness influenced the detection of 462 
glaucoma progression.  In addition, the inclusion of both so-called “pre-perimetric” glaucomas and 463 
glaucoma suspects (as defined by disc appearance) provided a basis for capturing very early disease. 464 
Some of these subjects showed no progression on either structural parameters and do not have, and 465 
may never develop glaucoma. We do not see this as a limitation, but as providing an important 466 
internal control. The subanalyses by disease and treatment status clearly showed the findings to be 467 
independent of both disease stage and treatment status. The present study indicates new insights 468 
into the initial manifestations of glaucoma by using longitudinal analysis with event based endpoints 469 
early in the disease process. 470 
 471 
Although this study revealed useful new insights into characteristics that influence SD-OCT GPA 472 
event analysis progression, we acknowledge potential limitatinos. The use of the CIRRUS SD-OCT 473 
event analysis algorithm to detect structural progression does present some limitations. Event 474 
analysis algorithms detect structural change by comparing the change in thickness from baseline for 475 
a given parameter to the reproducibility coefficient of a normative database.
26
 Without knowledge 476 
of this figure, due to proprietary reasons, it may be difficult to ascertain the false positive rate of 477 
progression. We attempted offset this uncertainty by only classifying eyes as showing SD-OCT 478 
progression when “likely loss” was confirmed twice. This stringent definition of progression 479 
combined with the high precision of SD-OCT imaging makes it extremely likely that the structural 480 
change detected on SD-OCT represents definite and progressive thinning of the mGCIPL or pRNFL. 481 
The fact that our findings were also replicated on visual field analysis further suggests that the 482 
change is real. Above all though, we elected for this methodology because it is an algorithm that is 483 
standardised across all CIRRUS pRNFL and mGCIPL monitoring and therefore well suited to real-484 
world glaucoma monitoring. Criticism may also arise because RNFL event analysis has been 485 
suggested to be less sensitive than RNFL trend analysis.
26
 There currently however exists a paucity of 486 
data comparing the sensitivities of mGCIPL event analysis and trend analysis algorithms to make a 487 
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similar claim. Hou et al have recently reported that mGCIPL GPA event analysis has a specificity >95% 488 
and that pRNFL GPA event analysis has a specificity >90% for progressive glaucoma, so it would 489 
appear that event analysis is well suited for detecting glaucomatous change.
1
 Another debate 490 
regarding event analysis could arise as to whether the nasal pRNFL regions influence the specificity 491 
of the glaucomatous structural progression analysis observed using the average pRNFL parameter. 492 
We have performed a further analysis (Supplementary table 2) which confirmed the major findings 493 
when pRNFL progression was confined to the inferior and superior regions more traditionally 494 
involved in glaucoma. 495 
 496 
We recognise that a potential limitation was that by permitting clinicians to treat participants at 497 
their discretion, patient treatment was therefore heterogeneous. We believe however that this 498 
model does possess some merits. This model provides maximum generalisability to the ophthalmic 499 
community treating Anglo-European individuals. It additionally enabled us to assess whether 500 
different glaucoma treatments affect the site of structural progression. We further assessed this 501 
limitation by including the maximum-recorded pre-treatment IOP and conducted a sub-analysis of 502 
treatment naive patient. The fact that this parameter was the most significant parameter and that 503 
the treatment naive subanalysis demonstrated higher levels of effect size indicates that differential 504 
treatment does not underlie the main outcomes of this study.  We also recognise a potential 505 
limitation that our population occupies a spectrum of both rate and stage of disease. We believe 506 
however that this provides an important application to the real-world glaucoma clinic, whereby 507 
patients do present at different stages of disease. For instance, the superiority of mGCIPL monitoring 508 
to detect progression in patients with thinner baseline pRNFL highlights the utility of mGCIPL in 509 
these patients.  510 
 511 
In conclusion, using a robust prospective study design with a large cohort and employing stringent 512 
definitions of SD-OCT progression, we found a significant association between maximum-recorded 513 
pre-treatment IOP, baseline pRNFL thickness, and earliest structural progression on mGCIPL or 514 
pRNFL. Specifically, longitudinal structural change in participants with lower pre-treatment IOP and 515 
thinner baseline pRNFL thickness tends to be detected on mGCIPL before pRNFL. These results 516 
support the clinical utility of using mGCIPL in addition to pRNFL imaging to monitor progression in 517 
glaucoma suspects and individuals with early manifest glaucoma, particularly in those with normal 518 
IOP and thinner pRNFL. 519 
520 
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Table 1: Analysis of patient demographics and medical history for mGCIPL-first and pRNFL-first 
progressing individuals 
 mGCIPL-first 
(n=134) 
pRNFL-first 
(n=111) 
P 
Patient demographics    
Age (years) 67.4 ± 9.2 64.8 ± 9.1 0.129 
Sex: male (%) 51.12 33.01 0.923  
Eye reaching endpoint: Right (%) 50.44 43.63 0.467 
Follow-up (months) 33.15 ± 13.21 30.12 ± 12.81 0.483 
Medical History    
Migraine (%) 58.84 41.22 0.254 
Hypertension (%) 43.07 24.29 0.025 
Antihypertensives (%) 38.05 19.81 0.017 
Baseline Systolic BP (mmHg) 132.61±20.34 130.30±18.54 0.296 
Baseline Diastolic BP (mmHg) 73.11±14.77 71.68±15.82 0.531 
Raynauds Phenomenon (%) 7.58 1.83 0.106 
Diabetes Mellitus (%) 11.63 14.32 0.566 
Depression (%) 19.52 17.97 0.233 
Myocardial Infarction (%) 8.31 8.92 0.964 
Stroke/TIA (%) 4.53 8.03 0.396 
Disc Haemorrhage (%) 14.55 8.23 0.113 
* p-value significant after Bonferroni correction (threshold = 0.05/36 = 0.001) 
p-values derived from univariate generalised linear models with mixed effects 
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Table 2: Ocular structural characteristics of eyes progressing on mGCIPL-first and pRNFL-first 
Structural Parameter mGCIPL-first 
(n=134) 
(μ±SD) 
pRNFL-first 
(n=111 
(μ±SD) 
P 
Baseline average pRNFL thickness (μm) 79.51 ± 10.93 86.58 ± 10.65 <0.001* 
Baseline pRNFL thickness in superior 
quadrant (μm) 
94.67 ± 16.58 102.61 ± 19.13 0.002 
Baseline pRNFL thickness in inferior 
quadrant (μm) 
97.94 ± 19.02 106.61 ± 19.13 0.006 
Baseline average mGCIPL thickness (μm) 73.66 ± 10.98 76.16 ± 7.98 0.104 
Baseline mGCIPL thickness in superior 
sectors (μm) 
74.02 ± 6.94 76.05 ± 9.78 0.056 
Baseline mGCIPL thickness in inferior 
sectors (μm) 
71.63 ± 8.39 75.83 ± 9.44 0.0114 
Central Corneal Thickness (μm) 550.02 ± 40.52 546.58 ± 37.98 0.536 
Optic disc area on Cirrus SD-OCT (mm
2
) 1.95 ± 0.44 1.99 ± 0.508 0.773 
Vertical Cup-Disc Ratio 0.68 ± 0.12 0.67 ± 0.11 0.144 
Spherical equivalent (dioptres) -0.07 ± 2.37 +0.19 ± 1.9 0.258 
* p-value significant after Bonferroni correction (threshold = 0.05/36 = 0.001) 
p-values derived from univariate generalised linear models with mixed effects 
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Table 3: Ocular Clinical characteristics (IOP and treatment history) of eyes progressing on mGCIPL-
first and pRNFL-first  
Ocular Clinical Characteristic mGCIPL-first 
(n=134) 
pRNFL-first 
(n=111) 
P 
Intra-Ocular Pressure    
Maximum recorded pre-treatment IOP 
(mmHg) 
18.53 ± 6.02 22.43 ± 6.12 <0.001* 
Maximum recorded IOP (mmHg) 20.44 ± 5.54 23.2 ± 6.0 0.001* 
Mean IOP during SD-OCT surveillance 
(mmHg) 
15.49 ± 2.65 18.87 ± 5.69 0.006 
Minimum recorded IOP (mmHg) 13.01 ± 2.56 14.46 ± 3.73 0.035 
Treatment History    
Participants treated medically prior to 
OCT progression (%) 
SLT (%) 
Trabeculectomy (%) 
41.79 
 
17.31 
0 
52.15 
 
29.22 
0.91 
0.174 
 
0.999 
0.934 
Patients with >1 medication (%) 15.67 17.11 0.553 
Cases treated with a Prostaglandin 
Agonist (%) 
34.32 39.64 0.596 
Cases treated with a Beta-blocker (%) 18.73 25.21 0.189 
Cases treated with an Alpha-2 agonist (%) 4.54 9.92 0.155 
Cases treated with a Carbonic Anhydrase 
inhibitor (%) 
8.21 6.31 0.506 
IOP = intraocular pressure. 
SLT = selective laser trabeculoplasty 
* p-value significant after Bonferroni correction (threshold = 0.05/36=0.001) 
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Macular GCIPL loss precedes peripapillary RNFL loss in glaucoma with lower intraocular pressure. 
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Supplementary table 1: Summary statistics for Glaucoma Suspect and Early Manifest Glaucoma cases.  
 
 Glaucoma Suspect 
(n = 146) 
Early Manifest  
(n = 89) 
p-value 
pRNFL first progressing cases (%) 41% 45% 0.020 
Maximum recorded pre-treatment 
IOP (mmHg) 
20.46± 6.15 19.33±5.27 0.062 
Baseline Average RNFL thickness 
(μm) 
84.32±10.72 78.71±11.23 <0.001 
Age (years) 65.06±9.18 68.61±9.28 0.003 
Sex: male (%)  44.46 42.8 0.866 
Eyes reaching endpoint: Right (%) 55.91 38.38 0.007 
 
Supplementary table 2: Replication of Results with exclusion of pRNFL average parameter 
 
 pRNFL-first 
(n = 95) 
mGCIPL-first 
(n = 134) 
p-value 
Maximum Pre-treatment IOP 
(mmHg) 
21.98±6.02 18.53±6.02 0.002 
Baseline average pRNFL thickness 
(μm) 
85.56±10.74 79.51±10.93  0.002 
 
As a review of our methodology, we performed an alternative analysis where the average pRNFL 
summary parameter was excluded from the definition of structural progression. Eyes were subsequently 
reclassified as pRNFL-first (based on either superior or inferior regions) or mGCIPL-first. 16 cases no 
longer exhibited pRNFL first progression and were excluded. To replicate the most significant findings, a 
generalised linear model with mixed effects was fitted to the maximum pre-treatment IOP and baseline 
average pRNFL thickness. Cases that demonstrated structural progression on pRNFL parameters first had 
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a significantly higher maximum pre-treatment IOP before treatment (P=0.002) and thicker baseline 
average pRNFL thickness (P=0.002).  
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
PRÉCIS 
 
Using guided progression analysis of optical coherence tomography, longitudinal glaucomatous 
structural change in individuals with lower IOP is detected sooner with macular ganglion cell-inner 
plexiform layer thickness than with peripapillary retinal nerve fiber layer thickness.  
